Key points are not available for this paper at this time.
Our study assessed the CD4 + /CD8 + ratio in people with HIV (PWH) switching from a second-generation integrase inhibitor regimen to long-acting cabotegravir (CAB) and rilpivirine (RPV). Over one year, we observed a significant improvement in the CD4 + /CD8 + ratio; In addition, our data showed that time spent in CAB+RPV was significantly associated with an increased CD4 + /CD8 + ratio. These findings suggest that long-acting therapy may enhance immune recovery, also in treatment-experienced PWH.
Muccini et al. (Thu,) studied this question.